ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS

Core Points - The proposed sale of iTeos Therapeutics, Inc. to Concentra Biosciences, LLC involves shareholders receiving $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] - Kahn Swick & Foti, LLC is investigating whether the proposed transaction adequately values iTeos and the process leading to this valuation [1] Company and Industry Summary - iTeos Therapeutics, Inc. is currently in a proposed transaction to be acquired by Concentra Biosciences, LLC [1] - The investigation by Kahn Swick & Foti, LLC is focused on the adequacy of the transaction consideration and the valuation of the company [1][2] - The transaction is structured as a tender offer, indicating that timing is critical for stakeholders [3]